🇺🇸 FDA
Patent

US 8034812

Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof

granted A61PA61P11/06A61P13/12

Quick answer

US patent 8034812 (Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof) held by Takeda Pharmaceutical Company Limited expires Mon Oct 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Oct 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61P, A61P11/06, A61P13/12, A61P15/08, A61P17/06